Clopidogrel pharmacogenomics: next steps: a clinical algorithm, gene-gene interactions, and an elusive outcomes trial.

Clopidogrel pharmacogenomics has received significant attention since a black box warning was announced by the Food and Drug Administration in March 2010.

This has left clinicians in a difficult situation where many questions remain unanswered.

In this brief viewpoint article, we ask some pointed questions of our own and outline the pathway that needs to be taken for clinical translation to occur.